Eli Lilly’s hottest drugs face a quiet new threat
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
The Source
THE STREET
Business
Citi revamps oil price target as Hormuz fears ease
THE STREET·1h ago·3 min read
Business
40-year-old water theme park abruptly closes doors before summer season
THE STREET·1h ago·3 min read
Business
Fast-growing, cult-favorite chain expands into new markets
THE STREET·1h ago·3 min read
Business
Convenience store chain shutters alcohol-only stores
THE STREET·1h ago·3 min read
Related
On this beat
Business
Why Decision-Making Frameworks Fail
HB·5h ago·3 min read
Business
Pizza Hut Sold to Two Firms for $2.7 Billion
TNYT·1h ago·3 min read
Business
Citi revamps oil price target as Hormuz fears ease
THE STREET·1h ago·3 min read
Business
Think You’re Getting an Uber Discount? Here’s Why That ‘Crossed-Out’ Price Might Be Fake
INC·1h ago·3 min read